FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation

BACKGROUND: BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways underlying BCR-ABL-independent tyrosine kinase inhibitor (TKI) resistance remain unclear. METHODS: In silico bioinformatic analysis was performed to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Taewoo, Sim, Kyu-Young, Ko, Gwang-Hoon, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Park, Sung-Gyoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892744/
https://www.ncbi.nlm.nih.gov/pubmed/35241148
http://dx.doi.org/10.1186/s13046-022-02298-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892744/
https://www.ncbi.nlm.nih.gov/pubmed/35241148
http://dx.doi.org/10.1186/s13046-022-02298-1

Ejemplares similares